Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney structure or function lasting more than three months and is staged by glomerular filtration rate (GFR) and albuminuria. Beyond its intrinsic morbidity, CKD transforms pharmacological management throughout the body: it alters drug clearance, causes accumulation of renally-excreted active metabolites, and contrainddicates agents that depend on adequate renal perfusion or excretion. At the same time, CKD generates three major systemic complications that require their own pharmacological management programs: anemia from erythropoietin deficiency, mineral bone disease from disordered calcium, phosphorus, and vitamin D metabolism, and accelerated cardiovascular disease from a cascade of uremic mechanisms. This module addresses drug dosing in CKD, the pharmacological strategies that slow CKD progression, and the management of anemia and mineral bone disease.
Chronic kidney disease (CKD) reduces the renal clearance of drugs and their metabolites in proportion to the fall in glomerular filtration rate (GFR). The clinical consequences range from modest dose adjustments at early stages to absolute contraindications at advanced stages. The first principle of CKD dose adjustment is identifying which drugs are predominantly renally cleared and what fraction of their activity is carried by renally-eliminated metabolites. Hepatically metabolized drugs with inactive metabolites may require little or no dose adjustment even in severe CKD, while drugs that are entirely renally excreted or have active renally-cleared metabolites require careful GFR-based modifications.112
Metformin is the prototype renally-eliminated drug requiring GFR-guided management. It is entirely renally excreted by tubular secretion, does not undergo hepatic metabolism, and accumulates in CKD in proportion to GFR decline, with accumulation predisposing to lactic acidosis through inhibition of hepatic gluconeogenesis and mitochondrial complex I. Current guidelines permit metformin continuation down to an estimated GFR (eGFR) of 30 mL/min/1.73 m² with dose reduction, require suspension at eGFR 30–45 mL/min/1.73 m² if acute kidney injury (AKI) risk is elevated (surgery, contrast exposure, illness), and contraindicate it below eGFR 30 mL/min/1.73 m².1 Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in CKD because they inhibit cyclooxygenase (COX)-dependent prostaglandin synthesis, removing the afferent arteriolar vasodilatory tone that maintains GFR in the setting of reduced nephron mass, and risk precipitating AKI.
Direct oral anticoagulants (DOACs) have varying degrees of renal elimination that determine their safety thresholds in CKD. Dabigatran is 80% renally eliminated and is contraindicated at eGFR below 30 mL/min/1.73 m²; apixaban has the lowest renal clearance of the DOACs (27%) and is the preferred anticoagulant in advanced CKD. Rivaroxaban (33% renal) and edoxaban (50% renal) require dose reduction or avoidance at lower eGFR thresholds. Gabapentin and pregabalin are both fully renally eliminated without hepatic metabolism and accumulate in CKD, causing sedation, ataxia, and respiratory depression at standard doses; dose reductions of 50–75% may be required at eGFR below 30 mL/min/1.73 m². Low molecular weight heparins (LMWHs), particularly enoxaparin, undergo renal elimination and accumulate in CKD, increasing bleeding risk; dose reduction or switching to unfractionated heparin (monitored by anti-Xa levels) is required at eGFR below 30 mL/min/1.73 m².1
Active metabolite accumulation represents a particularly dangerous form of CKD-related pharmacokinetic alteration because the parent drug may appear to be at a safe plasma level while the active metabolite that exerts the therapeutic and toxic effect accumulates silently. Morphine is the classic example: its principal active metabolite, morphine-6-glucuronide (M6G), is pharmacologically more potent than the parent compound and almost entirely renally cleared. In patients with CKD or acute kidney injury, M6G accumulates to concentrations that produce prolonged and severe opioid toxicity despite morphine doses that would be safe in patients with normal renal function. Hydromorphone and oxycodone also have active renally-cleared metabolites, though M6G accumulation with morphine carries the highest clinical risk. Fentanyl and methadone are alternatives with predominantly hepatic metabolism and no significant active renally-cleared metabolites, making them safer choices in advanced CKD.1
Morphine is commonly used in CKD patients for pain and dyspnea, but M6G (morphine-6-glucuronide) accumulates silently as GFR falls. M6G is 3–4 times more potent than morphine at the mu-opioid receptor and has a prolonged half-life in CKD. Patients can appear comfortable on a stable morphine dose, then develop progressive sedation, respiratory depression, and coma as M6G accumulates over days. Fentanyl (hepatic metabolism, no active renal metabolites) or hydromorphone at reduced doses with close monitoring are safer alternatives in CKD stages 4–5.
The renin-angiotensin-aldosterone system (RAAS) drives chronic kidney disease (CKD) progression through intraglomerular hypertension. Angiotensin II (Ang II) preferentially constricts the efferent arteriole of the glomerulus more than the afferent, elevating intraglomerular hydraulic pressure and increasing the transglomerular pressure gradient that drives protein filtration. Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II, and angiotensin receptor blockers (ARBs) block Ang II at the angiotensin type 1 (AT1) receptor; both reduce efferent arteriolar tone, lower intraglomerular pressure, and reduce the filtered protein load reaching the tubule. The reduction in proteinuria is not merely a surrogate: proteinuria is directly nephrotoxic through tubular inflammatory activation, and reducing it slows the tubulointerstitial fibrosis that is the final common pathway of CKD progression.2
Initiation of ACE inhibitors or ARBs in CKD typically produces an acute, predictable fall in glomerular filtration rate (GFR) as efferent arteriolar dilation reduces the driving pressure for glomerular filtration. This GFR dip is expected and acceptable up to 30% from baseline; it does not indicate nephrotoxicity and should not prompt drug discontinuation. A GFR decline exceeding 30%, or a rise in serum creatinine of more than 30% from baseline, warrants investigation for bilateral renal artery stenosis, severe volume depletion, or other causes of GFR-dependent hypoperfusion. Hyperkalemia is the other major safety concern: Ang II normally stimulates aldosterone secretion, which drives urinary potassium excretion; RAAS blockade removes this drive. Potassium should be checked within 1–2 weeks of initiation or dose increase, and the potassium-raising effect is amplified by concurrent use of mineralocorticoid receptor (MR) antagonists, epithelial sodium channel (ENaC) blockers, or potassium supplements.2
The evidence base for ACE inhibitor and angiotensin receptor blocker (ARB) renoprotection extends across CKD etiologies. In diabetic nephropathy, ACE inhibitors reduce the rate of doubling of serum creatinine and the progression to end-stage kidney disease (ESKD) independently of blood pressure lowering. In nondiabetic proteinuric CKD, a similar benefit has been demonstrated. The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial required baseline ACE inhibitor or ARB therapy in all enrolled patients, confirming that sodium-glucose cotransporter 2 (SGLT2) inhibitor renoprotection is additive to maximal RAAS blockade rather than a replacement for it. Dual RAAS blockade (simultaneous ACE inhibitor plus ARB) is not recommended because it amplifies hyperkalemia and acute kidney injury (AKI) risk without additional renoprotection, as demonstrated by the ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial).2311
Sodium-glucose cotransporter 2 (SGLT2) inhibitors block the SGLT2 transporter in the proximal convoluted tubule (PCT), reducing reabsorption of filtered glucose and sodium. The sodium delivery consequence is crucial: increased sodium delivery to the macula densa activates tubuloglomerular feedback (TGF), causing afferent arteriolar constriction that reduces intraglomerular pressure independently of blood glucose control. This hemodynamic mechanism explains why the renoprotective effects of SGLT2 inhibitors extend to patients without diabetes and are additive to the efferent arteriolar effects of renin-angiotensin-aldosterone system (RAAS) blockade. The combined effect of afferent constriction (SGLT2 inhibitors) plus efferent dilation (ACE inhibitors/ARBs) on intraglomerular pressure is synergistic, forming the mechanistic basis for combination therapy.34
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial randomized patients with type 2 diabetes and CKD (eGFR 30–90 mL/min/1.73 m², urinary albumin-to-creatinine ratio above 300 mg/g) on background ACE inhibitor or angiotensin receptor blocker (ARB) therapy to canagliflozin 100 mg daily versus placebo. The trial was stopped early at 2.6 years due to overwhelming efficacy: canagliflozin reduced the primary composite of end-stage kidney disease (ESKD), doubling of serum creatinine, and renal or cardiovascular death by 30% compared with placebo, establishing SGLT2 inhibition as a foundational CKD therapy.3 The DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial extended these findings to patients without diabetes: dapagliflozin 10 mg daily reduced the composite of sustained 50% eGFR decline, ESKD, or kidney/cardiovascular death by 39% versus placebo across the full enrolled population, with consistent benefit in diabetic and nondiabetic CKD subgroups.4
Beyond tubuloglomerular feedback, SGLT2 inhibitors reduce intraglomerular pressure through additional mechanisms: reduction in renal tubular oxygen consumption (by reducing the sodium reabsorption workload in the PCT) may protect against tubular hypoxia; anti-inflammatory effects reduce macrophage infiltration and pro-fibrotic cytokine production in the renal interstitium; and direct effects on proximal tubular cells may attenuate oxidative stress. These mechanisms collectively produce a rate of eGFR decline that is markedly slower than placebo even after the initial hemodynamic-mediated eGFR dip at drug initiation. The eGFR thresholds for SGLT2 inhibitors in CKD have been progressively revised: canagliflozin and dapagliflozin can be initiated at eGFR as low as approximately 20 mL/min/1.73 m² for their renoprotective and cardiovascular indications, and may be continued at eGFR approaching 15 mL/min/1.73 m² even though glycosuric efficacy is lost below eGFR 45 mL/min/1.73 m².3,4
The adverse effect profile of SGLT2 inhibitors in CKD requires systematic management. Genital mycotic infections (vulvovaginal candidiasis and balanitis) are the most common adverse effects, occurring in approximately 5–10% of users and caused by the glycosuric environment; patients should be counseled on hygiene and the need for reporting symptoms. Fournier gangrene (necrotizing fasciitis of the genitoperineal region) is rare but potentially fatal and has been reported with all agents in the class; patients with signs of perigenital infection require urgent evaluation. Euglycemic diabetic ketoacidosis (DKA) is an important and underrecognized risk: SGLT2 inhibitors promote ketogenesis by reducing insulin secretion and increasing glucagon, and in patients with type 1 diabetes, significant surgical stress, prolonged fasting, or low-carbohydrate diets, DKA can develop with near-normal blood glucose. SGLT2 inhibitors should be held for 3–4 days before major surgery and restarted only after oral intake is fully resumed.3,4
Heart failure reduces cardiac output and renal perfusion, activating RAAS and increasing tubular sodium reabsorption, which worsens congestion and accelerates CKD. SGLT2 inhibitors reduce tubular sodium reabsorption and intravascular volume, reducing cardiac preload and improving cardiac output, which in turn improves renal perfusion. Additionally, reduced afferent arteriolar pressure from tubuloglomerular feedback reduces hyperfiltration in the remaining nephrons. This bidirectional cardiorenal axis explains why SGLT2 inhibitors demonstrate consistent benefit in heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and CKD across trials.
Anemia of chronic kidney disease (CKD) arises primarily from deficient erythropoietin (EPO) production by peritubular fibroblasts in the renal cortex, which occurs as functioning nephron mass decreases. EPO is the principal glycoprotein hormone driving erythropoiesis: it binds the EPO receptor (EPOR) on burst-forming units erythroid (BFU-E) and colony-forming units erythroid (CFU-E) in the bone marrow, activating Janus kinase 2 / signal transducer and activator of transcription 5 (JAK2-STAT5) signaling that promotes erythroid proliferation, differentiation, and survival. With reduced EPO, erythroid precursor apoptosis increases and red cell production falls. Contributing factors include shortened red cell survival in the uremic environment, iron deficiency (both absolute and functional), and inflammation-driven upregulation of hepcidin, which traps iron in macrophages and reduces intestinal iron absorption.5
Erythropoiesis-stimulating agents (ESAs) are recombinant EPO receptor agonists used to treat anemia of CKD. Epoetin alfa is structurally identical to endogenous EPO with a half-life of approximately 8 hours when administered intravenously and 24 hours subcutaneously; it requires administration three times weekly in most patients. Darbepoetin alfa is a hyperglycosylated EPO analog with a half-life of approximately 25 hours intravenously and 48–72 hours subcutaneously, allowing once-weekly or once-every-two-weeks dosing; its extended half-life results from reduced receptor binding affinity offset by prolonged circulating time, producing equivalent erythropoietic activity at less frequent intervals. Subcutaneous administration produces more sustained plasma levels than intravenous for both agents, and subcutaneous administration is preferred in non-dialysis CKD patients; intravenous administration is used in dialysis patients to avoid injection burden.5
The target hemoglobin (Hgb) for erythropoiesis-stimulating agent (ESA) therapy in CKD was the subject of two pivotal trials that reshaped prescribing practice. The CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial randomized non-dialysis CKD patients to a target Hgb of 13.5 g/dL versus 11.3 g/dL and found that the higher target was associated with a significantly increased risk of the composite of death, myocardial infarction, hospitalization for heart failure, and stroke.10 The TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) trial confirmed this finding in diabetic CKD, demonstrating that darbepoetin targeting a Hgb above 13 g/dL increased stroke risk without reducing cardiovascular death or end-stage kidney disease (ESKD). Based on these trials, current guidelines recommend a target Hgb of 10–12 g/dL for most CKD patients on ESA therapy, with avoidance of Hgb above 13 g/dL.56
Iron is an absolute co-requirement for ESA therapy: ESAs drive erythropoiesis and rapidly deplete available iron stores, causing functional iron deficiency even when total body iron is not low. ESA hyporesponsiveness is the most common clinical problem in CKD anemia management, and the most common cause is iron deficiency. The threshold for treating iron deficiency in CKD patients on ESAs is a transferrin saturation (TSAT) below 20% or a serum ferritin below 100 ng/mL; iron supplementation should be optimized before ESA dose escalation. In dialysis patients, intravenous (IV) iron is strongly preferred over oral iron because hemodialysis patients have high ongoing iron losses (from blood in dialyzer tubing and blood sampling) and because oral iron absorption is impaired by hepcidin excess and uremic gastric dysfunction. IV iron formulations include ferric gluconate, iron sucrose, ferumoxytol, and ferric carboxymaltose, differing primarily in the dose per administration and infusion time.5
The CHOIR and TREAT trials showed that targeting Hgb above 13 g/dL with ESAs does not improve cardiovascular outcomes and increases stroke risk. The harm is believed to arise from ESA-driven erythropoiesis at supraphysiological EPO concentrations, which promotes platelet activation, thrombosis, and direct vasoconstriction through non-hematopoietic EPO receptor signaling on vascular smooth muscle. The current target is 10–12 g/dL, accepting some residual anemia rather than normalizing hemoglobin with escalating ESA doses.
Hypoxia-inducible factor prolyl hydroxylase domain inhibitor (HIF-PHI) agents represent a mechanistically distinct approach to chronic kidney disease (CKD) anemia. Under normoxic conditions, hypoxia-inducible factor 1-alpha (HIF-1α) is continuously hydroxylated at proline residues by prolyl hydroxylase domain (PHD) enzymes, targeting it for ubiquitination and proteasomal degradation via the von Hippel-Lindau (VHL) protein complex. Hypoxia inhibits PHD enzymes (which require oxygen as a cofactor), allowing HIF-1α to accumulate, translocate to the nucleus, dimerize with HIF-1β, and activate transcription of hypoxia-response genes including erythropoietin (EPO), transferrin, and transferrin receptor. HIF-PHIs are small-molecule competitive inhibitors of PHD enzymes that mimic hypoxia pharmacologically: they stabilize HIF-1α, increase endogenous EPO production from residual renal peritubular fibroblasts and hepatocytes, upregulate transferrin receptor expression to improve iron utilization, and reduce hepcidin expression to increase iron absorption. Oral administration is a significant practical advantage over injectable erythropoiesis-stimulating agents (ESAs), particularly for non-dialysis CKD patients.7
Roxadustat was the first HIF-PHI approved for CKD anemia and is available in multiple countries including China, Japan, and the European Union. Daprodustat received approval in the United States and Japan. In phase 3 trials, both agents raised hemoglobin comparably to ESAs in dialysis and non-dialysis CKD patients. However, roxadustat raised significant cardiovascular safety concerns at the US FDA review stage: pooled analyses suggested a possible increase in thromboembolic events and mortality compared with ESAs in dialysis patients, and the FDA issued a Complete Response Letter in 2021; the regulatory status in the US remains unresolved as of 2025. Daprodustat received US approval in 2023 based on non-inferiority cardiovascular outcomes data from the ASCEND-ND (Anemia Studies in CKD: Erythropoiesis via a Novel PHI, Non-Dialysis) and ASCEND-D (dialysis) trials. The class remains under active post-marketing surveillance for cardiovascular and thromboembolic safety.7
ESAs supply exogenous EPO at supraphysiological concentrations, bypassing the normal hypoxia-sensing feedback. HIF-PHIs stimulate endogenous EPO at lower, more physiological concentrations from residual renal and hepatic tissue, while also improving iron utilization and reducing hepcidin. In theory, this more physiological stimulation could avoid the non-hematopoietic EPO receptor-mediated vascular effects that contribute to ESA cardiovascular toxicity at high hemoglobin targets. Whether this translates to superior cardiovascular safety in practice is the central unresolved clinical question for the HIF-PHI class.
CKD-mineral bone disease (CKD-MBD) is a systemic disorder of calcium, phosphorus, and vitamin D metabolism caused by the loss of renal excretory capacity for phosphate and reduced renal 1-alpha-hydroxylase activity needed to convert 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol). As glomerular filtration rate (GFR) falls, phosphate retention stimulates fibroblast growth factor 23 (FGF-23) secretion from osteocytes, which reduces proximal tubular phosphate reabsorption (a compensatory response) and suppresses 1-alpha-hydroxylase, further reducing calcitriol production. Reduced calcitriol lowers intestinal calcium absorption and fails to suppress parathyroid hormone (PTH) transcription, resulting in secondary hyperparathyroidism. Elevated PTH mobilizes calcium from bone (osteitis fibrosa cystica at extremes), exacerbates phosphate retention, and contributes to vascular calcification through calcium-phosphate product elevation. FGF-23 elevation itself is an independent predictor of CKD progression and cardiovascular mortality, preceding the development of frank hyperphosphatemia by years.8
Phosphate binders are the pharmacological cornerstone of hyperphosphatemia management in CKD and dialysis patients. They act in the gastrointestinal (GI) tract by binding dietary phosphate and reducing its absorption, and must be taken with meals to be effective. Calcium carbonate is the least expensive binder but carries the risk of calcium loading, particularly in dialysis patients where positive calcium balance from both binder use and dialysate calcium promotes vascular calcification. Sevelamer carbonate is a non-calcium, non-aluminum polymeric binder that also has the additional benefit of reducing low-density lipoprotein (LDL) cholesterol by 15–30% through bile acid sequestration in the gut; it is preferred in patients at high cardiovascular risk or with documented vascular calcification. Lanthanum carbonate is a highly potent non-calcium binder with GI tolerability as its primary clinical limitation; it is chewable and must be taken with meals. Ferric citrate binds phosphate through iron-phosphate complex formation and simultaneously provides absorbable iron, making it a useful dual-purpose agent in iron-deficient CKD patients.8
Active vitamin D analogs suppress PTH by binding the vitamin D receptor (VDR) in parathyroid gland cells, reducing PTH gene transcription. Calcitriol, the naturally occurring fully active form of vitamin D (1,25-dihydroxyvitamin D), requires no renal activation and is the standard agent, but its lack of selectivity for parathyroid VDR means it also activates intestinal and vascular VDR, increasing calcium and phosphorus absorption and risking hypercalcemia and vascular calcification at higher doses. Paricalcitol is a selective VDR agonist with approximately 10-fold lower calcemic and phosphatemic activity than calcitriol at equivalent PTH-suppressing doses, reducing the risk of hypercalcemia; it is commonly used in dialysis patients requiring more aggressive PTH suppression. Doxercalciferol (1-alpha-hydroxyvitamin D2) requires hepatic conversion to its active form but similarly reduces PTH with lower hypercalcemic risk than calcitriol. Monitoring serum calcium and phosphorus is mandatory with all active vitamin D analogs, and therapy should be held if corrected calcium rises above 10.2 mg/dL or the calcium-phosphorus product exceeds 55 mg²/dL².8
Cinacalcet is a calcimimetic that allosterically activates the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing the sensitivity of the CaSR to extracellular calcium and reducing PTH secretion without raising serum calcium or phosphorus. It is approved for secondary hyperparathyroidism in dialysis patients and for parathyroid carcinoma. The EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events) trial enrolled dialysis patients with severe secondary hyperparathyroidism (PTH above 300 pg/mL) and found that cinacalcet did not significantly reduce the primary composite of cardiovascular death or cardiovascular events in the intention-to-treat analysis, though secondary analyses suggested possible benefit in younger patients. The principal adverse effects of cinacalcet are nausea, vomiting, and hypocalcemia, particularly when calcium is not monitored carefully after initiation; it should be held if corrected calcium falls below 7.5 mg/dL. Etelcalcetide is a second-generation calcimimetic administered intravenously at the end of each hemodialysis session, eliminating the compliance problem associated with oral cinacalcet in dialysis populations.89
Address dietary phosphate restriction first, then phosphate binders with meals. Control serum calcium and phosphorus before starting active vitamin D analogs. Add paricalcitol or calcitriol when PTH is persistently above 2–9 times the upper limit of normal for the CKD stage. Add cinacalcet or etelcalcetide when PTH remains elevated despite vitamin D analog therapy, particularly in dialysis patients. Avoid a calcium-phosphorus product above 55 mg²/dL² at all stages, as this threshold correlates with accelerated vascular calcification risk.
Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–1137.
doi:10.1038/ki.2011.322Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med. 2003;139(4):244–252.
doi:10.7326/0003-4819-139-4-200308190-00006Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
doi:10.1056/NEJMoa1811744Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
doi:10.1056/NEJMoa2024816KDIGO 2012 Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
doi:10.1038/kisup.2012.37Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032.
doi:10.1056/NEJMoa0907845Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis (ASCEND-ND). N Engl J Med. 2021;385(25):2313–2324.
doi:10.1056/NEJMoa2113380KDIGO CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59.
doi:10.1016/j.kisu.2017.04.001Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494.
doi:10.1056/NEJMoa1205624Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
doi:10.1056/NEJMoa065485Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
doi:10.1056/NEJMoa0801317Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314.
doi:10.1016/j.kint.2023.10.018